Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

Bookmark and Share
Published: 12 Jun 2020
Views: 431
Dr Katie Kelley - University of California San Francisco, San Francisco, USA

Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and tremelimumab for the treatment of advanced hepatocellular carcinoma.

She initially gives a thorough description of the trial design and rationale for the four study arms.

Dr Kelley proceeds to detail the results and whether the endpoints were met, and also some interesting outcomes from the biomarker analyses.

She looks forward to new data coming out, including the HIMALAYA trial.